- Home
- CALC
CALC
CalciMedica Inc.
as 07-26-2024 4:00pm EST
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 52.5M | IPO Year: | N/A |
| Target Price: | $20.50 | AVG Volume (30 days): | 35.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.75 - $8.38 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CalciMedica Inc. (CALC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WILSON ROBERT N | CALC | Director | Jun 28 '24 | Buy | $3.52 | 51,278 | $180,498.56 | 310,196 | SEC Form 4 |
| WILSON ROBERT N | CALC | Director | Jun 27 '24 | Buy | $3.23 | 8,443 | $27,304.66 | 258,918 | SEC Form 4 |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Apr 1 '24 | Buy | $3.90 | 746 | $2,909.40 | 36,640 | SEC Form 4 |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Apr 1 '24 | Buy | $3.90 | 3,254 | $12,690.60 | 39,894 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 243,356 | $900,903.91 | 946,744 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 144,676 | $535,590.55 | 727,433 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 194,472 | $719,935.34 | 435,148 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 51,032 | $188,920.46 | 114,260 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 13,184 | $48,807.17 | 27,609 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 3,920 | $14,511.84 | 21,602 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 28,744 | $106,410.29 | 30,292 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 243,356 | $900,903.91 | 946,744 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 144,676 | $535,590.55 | 727,433 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 194,472 | $719,935.34 | 435,148 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 51,032 | $188,920.46 | 114,260 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 13,184 | $48,807.17 | 27,609 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 3,920 | $14,511.84 | 21,602 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 28,744 | $106,410.29 | 30,292 | SEC Form 4 |
| WILSON ROBERT N | CALC | Director | Dec 11 '23 | Buy | $3.30 | 506 | $1,669.80 | 182,161 | SEC Form 4 |
| Leheny A. Rachel | CALC | Chief Executive Officer | Nov 6 '23 | Buy | $3.12 | 2,440 | $7,614.75 | 16,840 | SEC Form 4 |
| Leheny A. Rachel | CALC | Chief Executive Officer | Nov 3 '23 | Buy | $2.85 | 5,000 | $14,250.00 | 14,400 | SEC Form 4 |
| Hebbar Sudarshan | CALC | Chief Medical Officer | Nov 3 '23 | Buy | $2.74 | 36,000 | $98,600.40 | 46,000 | SEC Form 4 |
Latest CalciMedica Inc. News
CALC Breaking Stock News: Dive into CALC Ticker-Specific Updates for Smart Investing
PR Newswire
18 days ago
CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
PR Newswire
19 days ago
CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
Argus Research
24 days ago
Daily – Vickers Top Buyers & Sellers for 07/03/2024
PR Newswire
a month ago
CalciMedica Set to Join Russell Microcap® Index
PR Newswire
a month ago
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
PR Newswire
a month ago
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
Compare CALC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CALC CalciMedica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.